Cargando…
Clinical Efficacy of a 2-Week Treatment Course of Zuranolone for the Treatment of Major Depressive Disorder and Postpartum Depression: Outcomes From the Clinical Development Program
INTRODUCTION: Antidepressants that offer a rapid onset of action without requiring chronic use are greatly needed in both major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational, oral, neuroactive steroid and GABA(A) receptor positive allosteric modulator in...
Autores principales: | Clayton, A., Cutler, A.J., Deligiannidis, K.M., Lasser, R., Sankoh, A.J., Doherty, J., Kotecha, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567193/ http://dx.doi.org/10.1192/j.eurpsy.2022.282 |
Ejemplares similares
-
Rapid improvements in MADRS with zuranolone in major depressive disorder and postpartum depression: results from the LANDSCAPE/NEST clinical development programmes
por: Clayton, A. H., et al.
Publicado: (2023) -
Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial
por: Deligiannidis, Kristina M., et al.
Publicado: (2021) -
A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults
por: Bullock, Amy, et al.
Publicado: (2021) -
Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses
por: Lin, Yu-Wei, et al.
Publicado: (2023) -
Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression
por: Carlini, Sara V, et al.
Publicado: (2023)